We are live on
!
Find out more
FO
FT Options Portfolio holdings
AUM
$66.4M
1-Year Est. Return
18.48%
This Fund
S&P 500
This Quarter
Est. Return
+2.11%
1 Year Est. Return
+18.48%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$66.4M
AUM Growth
+$8.29M
(+14%)
Cap. Flow
+$122M
Cap. Flow
% of AUM
183.83%
Top 10 Holdings %
Top 10 Hldgs %
32.21%
Holding
297
New
108
Increased
49
Reduced
51
Closed
72
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Incyte
INCY
|
+$3.53M |
| 2 |
Teva Pharmaceuticals
TEVA
|
+$2.94M |
| 3 |
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
|
+$2.18M |
| 4 |
ARAV
Aravive, Inc. Common Stock
ARAV
|
+$1.54M |
| 5 |
SIOX
Sio Gene Therapies Inc. Common Stock
SIOX
|
+$1.37M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
General Mills
GIS
|
+$2.52M |
| 2 |
PTLA
Portola Pharmaceuticals, Inc.
PTLA
|
+$2.31M |
| 3 |
Amgen
AMGN
|
+$2.08M |
| 4 |
Abbott
ABT
|
+$1.72M |
| 5 |
CLVS
Clovis Oncology, Inc.
CLVS
|
+$1.56M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 41.81% |
| 2 | Consumer Discretionary | 7.1% |
| 3 | Consumer Staples | 6.25% |
| 4 | Communication Services | 0.99% |
| 5 | Materials | 0.21% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
GWPH
1
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
| $3.74M | 5.64% |
36,847
+3,290
| +10% | +$352K |
|
|
2
Incyte
INCY
$23.4B
| $3.26M | 4.91% |
+27,887
| New | +$3.53M |
|
|
3
Teva Pharmaceuticals
TEVA
$37.3B
| $2.3M | 3.47% |
+130,723
| New | +$2.94M |
|
4
CALL
Alnylam Pharmaceuticals
ALNY
$35.7B
| $2.1M | 3.17% |
+101,100
| New | +$8.63M |
|
|
TSRO
5
DELISTED
TESARO, Inc.
TSRO
| $1.87M | 2.81% |
14,462
+3,657
| +34% | +$454K |
|
|
CLVS
6
DELISTED
Clovis Oncology, Inc.
CLVS
| $1.79M | 2.71% |
21,787
-19,713
| -48% | -$1.56M |
|
7
Alibaba
BABA
$276B
| $1.71M | 2.58% |
9,900
| – | – |
|
8
CALL
Vertex Pharmaceuticals
VRTX
$123B
| $1.59M | 2.4% |
65,500
+6,500
| +11% | +$978K |
|
|
CLVS
9
CALL
DELISTED
Clovis Oncology, Inc.
CLVS
| $1.56M | 2.36% |
84,200
-61,000
| -42% | -$4.84M |
|
10
CALL
Akebia Therapeutics
AKBA
$359M
| $1.45M | 2.19% |
190,400
+39,100
| +26% | +$601K |
|
11
Puma Biotechnology
PBYI
$434M
| $1.37M | 2.06% |
+11,438
| New | +$1.06M |
|
|
TSRO
12
PUT
DELISTED
TESARO, Inc.
TSRO
| $1.34M | 2.03% |
31,000
-4,000
| -11% | -$497K |
|
|
KITE
13
CALL
DELISTED
Kite Pharma, Inc.
KITE
| $1.32M | 2% |
103,200
+77,900
| +308% | +$10.9M |
|
|
GWPH
14
PUT
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
| $1.32M | 1.99% |
71,000
+17,400
| +32% | +$1.86M |
|
15
Children's Place
PLCE
$65.8M
| $1.3M | 1.96% |
+11,000
| New | +$1.18M |
|
16
CALL
Insmed
INSM
$23.5B
| $1.28M | 1.93% |
222,000
+152,000
| +217% | +$2.9M |
|
17
iShares Biotechnology ETF
IBB
$9.23B
| $1.22M | 1.84% |
10,986
-9,255
| -46% | -$989K |
|
|
ICPT
18
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $1.18M | 1.77% |
+20,264
| New | +$2.18M |
|
19
Kimberly-Clark
KMB
$36B
| $1.14M | 1.72% |
+9,700
| New | +$1.18M |
|
20
Nike
NKE
$64.9B
| $1.06M | 1.59% |
+20,400
| New | +$1.15M |
|
21
CALL
Bristol-Myers Squibb
BMY
$124B
| $1.02M | 1.54% |
116,800
+60,300
| +107% | +$3.52M |
|
22
Henry Schein
HSIC
$10B
| $1.01M | 1.53% |
+15,744
| New | +$1.07M |
|
|
ZGNX
23
DELISTED
Zogenix, Inc.
ZGNX
| $939K | 1.42% |
+26,778
| New | +$363K |
|
24
Gilead Sciences
GILD
$167B
| $938K | 1.41% |
+11,581
| New | +$886K |
|
|
ALXN
25
DELISTED
Alexion Pharmaceuticals
ALXN
| $914K | 1.38% |
+6,518
| New | +$886K |
|
Similar funds
MC
FIM
TLIC
MKCM
ACM
MFM
VE
GFWEV
FT Options's Q3 2017 Portfolio in Review
As of Q3 2017, FT Options held 297 positions worth $66.4M, up 14% from $58.1M the previous quarter. Its ten largest holdings account for 32% of the portfolio.
FT Options deployed $122M of net new capital in Q3 2017, opening 108 new positions and adding to 49 existing holdings. Its largest new stake was Incyte: 27,887 shares worth $3.26M.
By sector, the portfolio is most concentrated in Healthcare at 42% of assets, up from 38% a quarter earlier, followed by Consumer Discretionary and Consumer Staples.
On the sell side, the largest reduction was General Mills, an estimated $2.52M trimmed.
- FT Options's largest Q3 2017 buy was Incyte: 27,887 shares worth $3.26M.
- FT Options added most to Sio Gene Therapies Inc. Common Stock in Q3 2017, an estimated $1.37M increase.
- FT Options's biggest Q3 2017 reduction was General Mills, cutting an estimated $2.52M.
- FT Options fully exited Portola Pharmaceuticals, Inc. in Q3 2017, selling an estimated $2.31M.
- FT Options's ten largest holdings make up 32% of its $66.4M portfolio in Q3 2017.
- FT Options opened 108 new positions and closed 72 in Q3 2017.
- FT Options's portfolio value rose 14% quarter-over-quarter to $66.4M.
Based on FT Options's 13F filing for Q3 2017, filed 13 Nov 2017.